Form 4: Tandem Diabetes Care: Executive Stock Unit Grant
Insider Transaction
Leigh Vosseller, EVP & CFO of Tandem Diabetes Care, received a grant of 62,657 Restricted Stock Units (RSUs) on May 29, 2026.
Summary
- Leigh Vosseller, Executive Vice President and Chief Financial Officer of Tandem Diabetes Care Inc., was granted 62,657 Restricted Stock Units (RSUs) on May 29, 2026.
- These RSUs represent a contingent right to receive either one share of common stock or cash in lieu thereof.
- Vesting of the RSUs is scheduled as follows: one-third on May 29, 2027, and the remaining two-thirds in eight equal quarterly installments thereafter.
- The grant is made under the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices and long-term incentive alignment rather than immediate financial performance.
Positives
- Grant of a significant number of Restricted Stock Units (62,657) to a key executive, indicating continued investment in leadership and potential future value.
- Clear vesting schedule provides a long-term incentive for the executive to remain with the company and contribute to its success.
Risks
- The value of the RSUs is subject to the future performance of Tandem Diabetes Care's stock price.
- Vesting is contingent on continued employment, meaning the executive could forfeit unvested RSUs if they leave the company before the vesting dates.
Future Outlook
The vesting schedule for the RSUs indicates a long-term commitment and incentive for the executive, with staggered vesting over approximately three years following the initial grant date.
Industry Context
StockSavvy.ai notes that the issuance of Restricted Stock Units to key executives is a common practice in the medical device industry to align executive compensation with long-term shareholder value and retention.
Stakeholder Impact
- Shareholders: The grant of RSUs is a form of compensation and does not directly impact current share price, but it aligns executive interests with long-term company performance.
- Employees: May signal continued investment in executive talent and a focus on long-term growth.
- Management: Reinforces the incentive structure for Leigh Vosseller to drive company performance.
Next Steps
- Vesting of RSUs according to the schedule: one-third on May 29, 2027, and the remainder in eight equal quarterly installments thereafter.
- Potential exercise or sale of vested RSUs by Leigh Vosseller, subject to company policies and market conditions.
Key Dates
| Date | Description |
|---|---|
| 04/19/2022 | Date of Power of Attorney for Dick P. Allen, Elizabeth A. Gasser, Kathleen McGroddy-Goetz, Susan M. Morrison, Rajwant S. Sodhi. |
| 04/20/2022 | Date of Power of Attorney for Peyton R. Howell, Rebecca B. Robertson, John F. Sheridan, Christopher J. Twomey. |
| 04/21/2022 | Date of Power of Attorney for Ricky A. Carpenter, Kathleen McGroddy-Goetz, Susan M. Morrison, Rajwant S. Sodhi. |
| 06/15/2022 | Date of Power of Attorney for Myoungil Cha, Joao Malagueira. |
| 06/21/2024 | Date of Power of Attorney for Jean-Claude Kyrillos. |
| 11/11/2025 | Date of Power of Attorney for Sandra W. Beaver. |
| 05/29/2026 | Transaction Date for the grant of Restricted Stock Units to Leigh Vosseller. |
| 05/29/2027 | First vesting date for one-third of the RSUs granted to Leigh Vosseller. |
| 06/02/2026 | Date of signature for Power of Attorney by Jerilyn Laskie, Attorney-in-Fact for Leigh A. Vosseller. |
Keywords
Tandem Diabetes Care, TNDM, Form 4, Restricted Stock Units, RSU, Executive Compensation, Stock Options, Insider Trading, SEC Filing, Vesting Schedule, Long-Term Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.